Cardiovasc

Emerging role of NLRP3 inflammasome as a therapeutic target in cardiovascular and infectious diseases

  • Chair(s):

    Na Li,
    Assistant Professor,Department of Medicine, Baylor College of Medicine, Houston, TX, The United States of America

    Shigeki Miyamoto,
    Associate Professor,Department of Pharmacology, University of Califonia - San Diego, San Diego, CA, The United States of America

  • Session description:

    The development of inhibitors targeting NLRP3 inflammasome
    Dr Rebecca Coll
    Lecturer, Queen’s University Belfast, Belfast, United Kingdom

    CaMKII signaling and NLRP3 inflammasome activation in cardiomyocyte mediated inflammation
    Professor Shigeki Miyamoto
    Associate Professor, Department of Pharmacology University of California, San Diego, San Diego, CA, The United States of America

    Oral communication speaker - to be confirmed in 2022.

    Pathological role of NLRP3 inflammasome in the development of atrial fibrillation
    Dr Marcel Tekook
    Department of Pharmacology, University of Duisburg – Essen Germany, Essen, Germany

    Inflammasome activation and COVID-19 patients
    Stefano Toldo Assistant Professor of Medicine, Department of Internal Medicine, Virginia Commonwealth University, Virginia, USA

  • 00

    days

  • 00

    hours

  • 00

    minutes

  • 00

    seconds

Date

03 Jul 2023

Time

4:05 pm - 6:30 pm

Speakers

Leave A Comment